XRCC6

X-ray repair cross-complementing protein 6

750 patent compounds predicted against XRCC6, 224 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13346489	0.67	3/20
SCHEMBL30436407	0.67	3/20
SCHEMBL31060848	0.67	3/20
SCHEMBL13346492	0.54	3/20
SCHEMBL31060688	0.54	3/20
SCHEMBL3536668	1.00	2/20
SCHEMBL31060252	1.00	2/20
SCHEMBL7327543	0.71	2/20
SCHEMBL29161388	0.71	2/20
SCHEMBL3542251	0.66	2/20
SCHEMBL13435723	0.66	2/20
SCHEMBL31060404	0.66	2/20
SCHEMBL610237	0.65	2/20
SCHEMBL29374897	0.65	2/20
SCHEMBL30943704	0.65	2/20
SCHEMBL30943705	0.65	2/20
SCHEMBL7320358	0.62	2/20
SCHEMBL7329165	0.59	2/20
SCHEMBL7315961	0.57	2/20
SCHEMBL7320037	0.57	2/20

Germline variants in XRCC6 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full XRCC6 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to XRCC6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency	PHASE2/PHASE3	RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma	PHASE1/PHASE2	COMPLETED
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations	PHASE2	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer	PHASE1	COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
Chromosomal Translocations in Chandigarh Police	nan	COMPLETED
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base	nan	RECRUITING
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews	nan	COMPLETED
Prognostic Biomarkers in Patients With Urothelial Carcinoma	nan	COMPLETED
Telomere Repair Gene Mutation in Inflammatory Bowel Disease	nan	COMPLETED
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility	nan	RECRUITING
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED
The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a XRCC6 binder may also engage these)

Protein	Name	Similarity
O93257	—	1.000	O93257 →
P23475	—	0.999	P23475 →
Q6DDS9	—	0.986	Q6DDS9 →
XRCC5	X-ray repair cross-complementing protein 5	0.985	landscape →
Q803R5	—	0.981	Q803R5 →
NAT10	RNA cytidine acetyltransferase	0.980	landscape →
Q5R981	—	0.978	Q5R981 →
P33611	—	0.978	P33611 →
Q8N1G2	—	0.978	Q8N1G2 →
Q5U2Z5	—	0.978	Q5U2Z5 →
Q9IAM7	—	0.978	Q9IAM7 →
Q9UJA3	—	0.977	Q9UJA3 →
Q8VI84	—	0.977	Q8VI84 →
Q5F310	—	0.977	Q5F310 →
P31669	—	0.977	P31669 →
Q9DBC3	—	0.976	Q9DBC3 →
O42131	—	0.976	O42131 →
Q8N3U4	—	0.976	Q8N3U4 →
PRMT5	Protein arginine N-methyltransferase 5	0.976	landscape →
P54358	—	0.976	P54358 →
Q64511	—	0.976	Q64511 →
P42348	—	0.976	P42348 →
I0IUP3	—	0.976	I0IUP3 →
Q2TAF4	—	0.976	Q2TAF4 →
P27641	—	0.975	P27641 →
Q28Z41	—	0.975	Q28Z41 →
Q6NUA1	—	0.975	Q6NUA1 →
Q38899	—	0.975	Q38899 →
Q6GNS3	—	0.975	Q6GNS3 →
Q8AVL0	—	0.975	Q8AVL0 →